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Available online xxxxObjective: So that informed treatment decisions can be made, clinical trials need to evaluate treatments against
domains that are important to people with epilepsy (PWE), their carers, and clinicians. Health professionals
have identiﬁed domains of importance to them via the International League Against Epilepsy's Commission on
Outcome Measurement (COME). However, patients and carers have not been systematically asked.
Methods: Via themembership of the British Epilepsy Association, we recruited and surveyed 352 PWE and 263 of
their informal carers. They were presented with 10 outcome domains (including the 5 identiﬁed by COME) and
asked to rate their importance using a 9-point Likert scale. They were also asked to identify any additional
domains of importance.
Results: The patients' mean age was 49 years, the median number of years since diagnosis was 20, and 65% had
experienced seizures in the prior 12 months. Most carers were the spouse or parent. Patients' and carers'
mean ratings indicated that their outcome priorities were similar, as were those of patients who had and had
not experienced recent seizures. There was consensus among patients that 6 domains were of critical impor-
tance. These included the 5 identiﬁed by COME (namely, and in order of importance, the effects of the treatment
on “Seizure severity”, “Seizure frequency”, “Quality of life”, “Cognitive function”, and “Adverse events”), aswell as
one additional domain (“Independence/need for support”). There was consensus among carers that the 5 COME
domainswere also critically important. They, however, identiﬁed 3 further domains as critically important. These
were the effects of the treatment on patient “Depression”, “Anxiety”, and “Independence/need for support”.
Conclusions: Our study found some overlap between the priorities of PWE, carers, and health professionals. They,
however, highlight additional areas of importance to patients and carers. Our results could inform a core outcome
set for epilepsy that represents the domains that should be reported as aminimumby all trials. This could promote
trials which produce meaningful results and consistency in measurement and reporting.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Core outcome1. Introduction
A variety of pharmacological and nonpharmacological treatments
have been developed to help peoplewith epilepsy (PWE)with theman-
agement of seizures and comorbidities. Choosing which treatment to
receive can be complex, not least because all treatments have the poten-
tial for harm and beneﬁts. The results of randomized controlled trials
should be able to help treatment decisions. Unfortunately, interpreting
the results of epilepsy trials can be challenging [1,2], and it is unclear
whether the information they report is meaningful to patients. Why?
This is because there is considerable variability in the aspects oflogical Sciences, Institute of
iversity of Liverpool, Liverpool
5537.
. This is an open access article underoutcome that trial investigators measure and report and because there
has been no systematic effort to ask patients and carers what
outcomes are important to them [3–5].
In line with regulatory guidance [6], success within a placebo-
controlled antiepileptic drug (AED) trial in people with refractory
epilepsy is frequently judged bywhether a person experiences a seizure
frequency reduction of ≥50%. This criterion might, though, be arbitrary
and not align with patients' preferences. Improving the design of epi-
lepsy trials and increasing the applicability of their evidence to clinical
practice have been identiﬁed as a priority [1,2,7–10]. Some recommen-
dations have been made concerning which outcomes epilepsy trials
should measure [11,12] — the most notable being those of the Interna-
tional League Against Epilepsy's (ILAE) Commission on Outcome Mea-
surement in Epilepsy (COME) [11]. However, these were made on the
basis of round table discussions between representatives from some
health professions. It has not been established whether the priorities
of patients and families regarding outcomes are the same.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ble that patients and familiesmaywant information about a treatment's
effect on aspects of outcome beyond seizure frequency. Gilliam [13], for
instance, found patient-perceived quality of lifewas associatedwith the
experience of adverse events and depression, not seizures, while Smith
et al. [14] found that improvements in seizure severity helped explain
why some patients continued to take lamotrigine, despite experiencing
no reduction in seizure frequency. For reasons such as these, some trials
have captured information about the effect of a treatment on outcomes
beyond seizure frequency. However, many have not.
For other conditions, there have been efforts to form consensus on
what aspects of outcome are most important to people affected by that
condition and clinicians [15–21]. This is thenused to forma ‘core outcome
set’ (COS). Core outcome sets are not extensive lists of outcomes but
rather a few particularly important ones that should be reported as a
minimum by trials in that condition [22,23]. The existence of a COS does
not preclude inclusion of additional relevant outcomes for a given trial.
No COS exists for epilepsy trials [24]. Having one could facilitate
trials which produce evidence relevant to stakeholders. It could also
help reduce reporting bias and make evidence synthesis easier
[25–27]. All but 3 of the 20 most accessed and cited epilepsy Cochrane
Reviews in 2014 described problems due to inconsistencies in the out-
comes reported by trials [28–38]. It is for reasons such as these that
COSs are becoming supported by journal editors and research funders
[39,40].
To develop a COS for epilepsy and promote uptake, amomentum for
change needs to be established, and research is required. A variety of
approaches could be used to develop the COS [41]. These include expert
panel meetings and Delphi surveys.Whichever is used, a key part of the
exercise should be for evidence to be considered on which outcomes
PWE and carers consider most important. There is published evidence
on the subjective experience of epilepsy [42,43], but there is none on
patients' and carers' priorities for outcomes in trials.
Therefore, to assist with the development of an epilepsy COS, we
surveyed a large and diverse sample of PWE and informal carers about
the importance they attached to outcome domains that have been
recommended for use in trials. We asked patients and carers to also
identify additional outcome domains of importance to them and sought
to determine whether the priorities of patients and carers differed and
whether any differences existed between patientswhowere continuing
to experience seizures and those who were not.
2. Methods
2.1. Participants
Participants were PWE afﬁliatedwith the British Epilepsy Association
(Epilepsy Action) and their informal carers. All participants were aged
≥16 years, and patients needed to report a diagnosis of epilepsy (of any
type) for at least one year. People were excluded if they could not pro-
vide informed consent or independently complete questionnaires in
English.
2.2. Procedure
Datawere collected as part of a larger, longitudinal study. The purpose
of that study was to examine how similar ratings of patient outcomes
made bypatients themselveswere to thosemade by their informal carers.
As part of that study, patients and carers completed a questionnaire pack
that asked them to make ratings of outcomes on a number of measures
upon recruitment and then again 12 months later. Of relevance to the
current report, the questionnaire pack completed by patients and carers
upon recruitment also asked them about the importance they ascribed
to different outcome domains in the context of a trial.
With regard to recruitment, the British Epilepsy Association main-
tains a database of people, including patients, carers, and interestedparties, who are willing to be contacted by the Association. Three thou-
sand eight hundred sixty-six people were randomly selected from this
database in 2013, and invitations to participate in the larger study
were posted. Attached to the invitation was a questionnaire pack for
PWE, as well as a pack for them to pass on to a familymember or friend.
The University of Liverpool's Institute of Psychology, Health and
Society Research Ethics committee approved the study (1213-LB-093).
Informed consent was obtained from all participants.
2.3. Measures
2.3.1. Characteristics
Participants were asked as part of the questionnaire pack to report
their demographics and medical history. For patients, this included
age at diagnosis, who they considered to be their main epilepsy doctor,
and number of different antiepileptic drugs currently prescribed. Thapar
et al.'s [43] scale was used to capture the number of seizures (of any
type) the patient had experienced in the previous 12 months.
2.3.2. Importance of different outcome domains
Participants were presented with the following instructions which
were adapted fromCOS studies in other ﬁelds [16,44]: “New treatments
for epilepsy are tested to see how helpful they are. We want to know
which things you feel should be looked at and reported onwhen testing
a new treatment. Please tell us how important you feel each of
the things below is”. Patients and carers were then asked to rate the
importance of different domains.
The 10 domains that theywere asked to rate included the 5 domains
which the ILAE COME suggested [11]— namely, the effects of the treat-
ment on i) “Seizure frequency”, ii) “Seizure severity”, iii) “Adverse
events”, iv) “Cognitive function”, and v) “Quality of life”. On the basis
of qualitative evidence concerning the impacts which epilepsy can
have from the patient perspective [42], participants were asked to rate
the importance of 5 additional domains. These were the effects of the
treatment on vi) “Depression”, vii) “Anxiety, viii) “Independence/need
for support”, ix) “Felt stigma”, and x) “Economic cost” (in this case, to
the health service provider since this study was conducted within the
context of publicly fundedhealth servicewhich is free at the point of de-
livery). The headings given to the different domains within the ques-
tionnaire are shown in Table 2.
Respondents were asked to score the importance of each domain
using the 9-point Likert scale proposed by the GRADE (Grading of
Recommendations Assessment, Development and Evaluation) group
(http://www.gradeworkinggroup.org), in which 1 to 3 signiﬁes an
outcome of “Little importance”, 4 to 6 as “Important”, and 7 to 9 as
“Very important”. This scoring system has been used in other COS
studies to discriminate the importance of different domains [16,45,46].
In order to not overlook other domains of importance to patients and
carers, participants were invited to record other aspects of outcome
that were important to them.
The questionnaire was piloted to check face validity, understanding,
and acceptability.
2.4. Statistics
The primary objectivewas to identify the importance of the different
domains to patients and informal carers. There are no guidelines for the
numbers of participants required to develop a COS [47]. However, given
the heterogeneity of epilepsy, we followed other COS studies [16]
and considered that approximately 300 PWE and 300 carers would be
necessary to ensure all relevant groups were sampled adequately.
Descriptive statisticswere used to examine participants' characteris-
tics and the importance they ascribed to each outcomedomain. For each
domain, the mean importance rating given to it by participants is
presented, and the domains have been ranked by the proportion of pa-
tients and carers that identiﬁed them as being “Very important” (score:
Table 1
Participants' characteristics.
Patients
(N = 352)
Carers
(N = 263)
Age
Mean (SD) 49.1 (15.7) 56.02 (14.40)
Range 16–94 16–92
Sex (n/%)
Female 224 (63.6) 160 (60.8)
Ethnicity (n/%)
White British 342 (97.2) 255 (97.0)
Other 10 (2.8) 8 (3.0)
Highest educational attainment (n/%)
Basic school certiﬁcate or lower 200 (56.8) 153 (58.2)
Advanced school certiﬁcate or higher 152 (43.2) 110 (41.8)
Employment (n/%)
Employed (full/part-time) 127 (36.1) 137 (52.1)
Student 10 (2.8) 6 (2.3)
Retired because of age 57 (16.2) 71 (27.0)
Retired because of ill health 61 (17.3) 13 (4.9)
Homemaker 18 (5.1) 19 (7.2)
Unemployed 53 (15.1) 10 (3.8)
Other 26 (7.4) 7 (2.7)
Main epilepsy doctor (n/%)
Primary care 110 (31.2) –
Hospital specialist 242 (68.8)
Years diagnosed
Median (IQR) 20.0 (8–37) –
Antiepileptic medication (n/%)
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rately to ensure that outcomes important to the two groups could be
identiﬁed.
Interpreting what rating qualiﬁes an outcome for inclusion in or ex-
clusion from a COS remains debated. We followed Williamson et al.'s
[41] suggestion that consensus on whether a domain should be includ-
ed can be understood to be present when ≥70% of participants rate the
domain as being “Very important”, and b15% rated it as of “Little impor-
tance” (score: 1 to 3) [16,41,46].
Independent samples t-tests compared themean importance scores
provided by patients and those provided by carers for each domain, as
well as the mean importance scores given to the domains by patients
who had experienced a seizure in the prior year to those given by
patients who had not.When comparing patients' and carers' scores, dif-
ferences were calculated by subtracting the carers' mean ratings from
those of the patients.When comparing the ratings of patients by seizure
status, the scores of those with ongoing seizures were subtracted from
the scores of thosewhohad not experienced seizures.Mean differences,
along with 95% conﬁdence intervals (CIs), are reported.
Where free-text responses were provided by participants regarding
additional domains, these were extracted by AN, grouped where
possible, and reported using broad headings.
All analyses are based on actual response data; no responses
were imputed. Analyseswere performed using SPSS 22.0 (IBM, Armonk,
NY, USA).None 6 (1.7) –
Monotherapy 153 (43.4)
Polytherapy 193 (54.9)
Seizures (any type) in the prior 12 monthsa,b (n/%)
Yes 229 (65.2) –
No 122 (34.8)
Median (IQR) 4.0 (0–10)
Medical history (beyond epilepsy for patients) (n/%)
None 142 (40.3) 162 (61.6)
Another medical diagnosis 159 (45.2) 88 (33.5)
Psychiatric diagnosis 17 (4.8) 4 (1.5)
Both medical and psychiatric diagnoses 34 (9.7) 9 (3.4)
Relationship to patient
Spouse/partner – 140 (53.2)
Parent 80 (30.4)
Friend 20 (7.6)
Child 12 (4.6)
Other 11 (4.2)
Notes: IQR = interquartile range, n = number, SD = standard deviation.
a Thapar et al.'s [43] scale which asks “How many attacks have you had in the last
12 months?”. The patient can choose from the following ordinal categories: 0, 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, or more.
b Seizure frequency data missing for 1 patient participant.3. Results
3.1. Participants
From the 3866 invitations sent, 352 PWE agreed to participate in the
study and returned a completed questionnaire, as did 263 informal
carers. Of the remaining invitations, 180 were returned as the person
no longer resided at the address, 14 recipients responded to say that
theywere not eligible, 4 PWE actively declined to participate, and 36 re-
sulted in incomplete questionnaires being returned. No responses were
received for the remaining 3283 (84.9%) invitations.
The characteristics of the participants are shown in Table 1. With re-
spect to patients, themean agewas 49.1 years (standard deviation [SD]:
15.7), and 63.6% were female. The median time since diagnosis was
20.0 years (interquartile range [IQR]: 8–37), most (65.2%) had experi-
enced a seizure (of some type) within the prior 12 months, and 60%
reported at least one comorbidity. In terms of the carers, their mean
age was slightly older at 56.02 years (SD: 14.4), and most were female
(60.8%). Most were either a spouse/partner to the patient (53.2%) or a
parent (30.4%).3.2. Importance of different outcome domains
Eight of the domains were given a mean importance rating of ≥7 by
both patients and carers— indicating that these domains were typically
rated as being “Very important” from their perspective (Table 2). The
only two domains not to receive such a high average importance rating
were “Felt stigma” and “Economic cost”.
When applyingWilliamson et al.'s [41] criteria, consensus on the im-
portance of a domain was present for 6 of the 10 domains from the pa-
tients' perspective and for 8 of the domains from the carers' perspective.
For patients, these domains were “Seizure severity” (89.5%), “Seizure
frequency” (87.5%), “Quality of life” (85.8%), “Cognitive function”
(84.4%), “Adverse events” (84.1%), and “Independence/need for sup-
port” (73.9%). For carers, the domains were “Quality of life” (91.6%),
“Adverse events” (89.0%), “Seizure frequency” (89.0%), “Seizure
severity” (86.7%), “Cognitive function” (85.2%), “Depression” (80.2%),
“Anxiety” (75.7%), and ﬁnally, “Independence/need for support” (75.3%).3.3. Additional domains of importance
Only 48 (13.6%) of the patient participants and 31 (11.8%) of
the carers identiﬁed additional domains of importance. Most of these
patients (93.8%) and carers (87.1%) identiﬁed just one domain.
There was substantial overlap in the additional domains noted,
which permitted their categorization. In descending order of how fre-
quently they were noted, patients identiﬁed the following domains:
“the effect of the treatment if taken when pregnant” (43.8%), “how the
treatment interacts with other treatments I am receiving” (33.3%),
“the complexity of taking and storing the treatment” (18.8%), “the ethics
of the treatment's production, including the use of animals and carbon
emissions” (6.3%), and “the effect of the treatment on comorbid condi-
tions” (4.2%). The domains identiﬁed by carers were “how the treat-
ment interacts with other treatments the patient is receiving” (41.9%),
“the complexity of taking and storing the treatment” (35.5%), and “the
effect of the treatment if taken when pregnant” (29.0%).
Table 2
Ratings of importance given to the outcome domains by patients and by carers.
Domain Patients (N = 352) Carers (N = 263)
Rank % rated as
“Very
important”
(7–9)
% rated as
“Little
importance”
(1–3)
Mean
score (SD)
Rank % rated as
“Very
important”
(7–9)
% rated as
“Little
importance”
(1–3)
Mean
score (SD)
Mean difference
(95% CI)
P-value
Seizure severity
“The treatment's effect on how many
seizures you have”
1 89.5% 2.0% 8.22 (1.46) 4 86.7% 3.8% 8.15 (1.68) 0.07 (−0.18, 0.32) 0.595
Seizure frequency
“The treatment's effect on how
severe your seizures are”
2 87.5% 2.8% 8.24 (1.55) 2= 89.0% 2.3% 8.31 (1.48) −.07 (−0.32, 0.17) 0.531
Quality of life
“The treatment's effect on your
quality of life”
3 85.8% 2.6% 7.97 (1.62) 1 91.6% 1.1% 8.35 (1.26) −0.38 (−0.61,−0.15) 0.001
Cognitive function
“The treatment's effect on your
mental skills (such as, memory,
concentration, and thinking)”
4 84.7% 3.4% 7.94 (1.69) 5 85.2% 2.7% 7.95 (1.65) −0.01 (−0.27, 0.26) 0.962
Adverse events
“The side effects that the treatment
has on you”
5 84.1% 2.6% 8.01 (1.66) 2= 89.0% 1.1% 8.17 (1.40) −0.17 (−0.41, 0.08) 0.192
Independence
“The treatment's effect on how much
support/care you need from your
family and friends”
6 73.9% 8.2% 7.28 (2.19) 8 75.7% 6.8% 7.43 (2.13) −0.15 (−0.50, 0.19) 0.381
Depression
“The treatment's effect on mood/
how depressed you feel”
7 69.3% 6.3% 7.32 (2.12) 6 80.2% 3.8% 7.76 (1.82) −0.44 (−0.75,−0.12) 0.006
Anxiety
“The treatment's effect on worry/
your anxiety levels”
8 67.6% 8.0% 7.10 (2.21) 7 75.7% 5.3% 7.52 (1.93) −0.41 (−0.74,−0.08) 0.014
Felt stigma
“The treatment's effect on how
stigmatized you feel by epilepsy”
9 52.6% 21.0% 6.17 (2.79) 9 58.6% 12.9% 6.62 (2.43) −0.45 (−0.86,−0.03) 0.034
Economic cost
“How much the treatment costs
the health service”
10 33.9% 36.2% 4.86 (2.94) 10 25.9% 46.4% 4.30 (2.99) 0.56 (0.08, 1.03) 0.021
Notes: CI= conﬁdence interval, SD= standard deviation. Ranking is based on the proportion of participants within the sample that rated the domains as being “Very important” (score: 7–9).
For carers, domain labels were adjusted so as to be in reference to the patient, rather than themselves (e.g., “The treatment's effect on how severe the seizures are that the personwith epilepsy
that youknowhas”wasused insteadof “The treatment's effect onhowsevere your seizures are”). Entries inbold indicate statistically signiﬁcant differences (Pb 0.05).= indicates a tiedposition
in ranking when based on the percentage of participants who rated the domain as being "Very important".
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3.4.1. Patients versus carers
For most of the domains (8/10), the mean ratings given by carers
were slightly higher than those reported by patients, indicating that
carers attributed more importance to the domains than patients
(Table 2). For 5 domains, namely, “Quality of life”, “Depression”,
“Anxiety”, “Felt stigma”, and “Economic cost”, the difference between
the patients' and carers' ratings was statistically signiﬁcant. However,
the magnitude of the differences was small, with all mean differences
being b1 point.
3.4.2. Patients with versus patients without seizure/s in the prior 12months
There were no statistically signiﬁcant differences in themean scores
of these two subgroups, and all mean differences were b1 point
(Supplementary Table 1). Moreover, when looking at which domains
were rated as being “Very important” by ≥70%, the two subgroups
identiﬁed the same 6 domains.
4. Discussion
4.1. Main ﬁndings
To help understand what the key outcome domains are to adults
with epilepsy and their informal carers, we, for the ﬁrst time, asked pa-
tients and carers to rate the importance they attributed to 10 outcomedomains and invited them to suggest additional ones. The views of
over 600 people were obtained.
On the basis of roundtable discussions among health professionals,
the ILAE COME [11] had suggested outcome domains which epilepsy
drug trials should measure. As well as seizure frequency, they recom-
mended measuring seizure severity, quality of life, cognitive function,
and adverse events. We found that patients and carers also viewed
each of these domains as being critical. This is an important ﬁnding in
itself and conﬁrms that the effect a treatment has on seizure frequency
is only one of the pieces of information which service users want when
evaluating the beneﬁt of a treatment for health.
Our results, however, expand the work of the ILAE COME as we
found that there was consensus among patients that an outcome mea-
sure relating to their independence/how much support they require
from others should also be included in trials and reported, while the
views of carers indicated that they would want the inclusion of three
further measures— namely, measures relating to the effect of the treat-
ment on patients' independence, depression, and anxiety levels.
We also asked participants to write down additional domains which
they considered to be important. Most participants did not. This
suggests that the domains they were presented with captured their
main priorities. The additional domains that were most frequently
noted related to the complexity of the treatment regime, aswell as the ef-
fect of treatment onwomenwhowere pregnant. That these are priorities
of service users concords with the wider literature. Treatment adherence
is related to dosing complexity [48], and we know that one-third of
people treated for epilepsy are women of child-bearing age [49].
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as well as the views of patients who had experienced seizures in
the 12 months preceding participation to those of patients who had
not. We did not ﬁnd any meaningful differences between these
groups. This suggests that the importance of the domains is consis-
tent across these groups. This is important when considering
the scope and applicability of the provisional COS that our results
indicate. Future studies should, however, evaluate the relevance
of other characteristics, such as whether a patient has a new or
established diagnosis of epilepsy.4.2. Strengths and weaknesses
Strengths of our study include it being the ﬁrst study to elicit the
opinions of PWE and their carers on outcome priorities and that a
large sample was surveyed. That our study was completed within the
context of the UK health service is also advantageous. Like those in the
majority of Western countries, healthcare in the UK is predominately
publicly funded [50]. This could suggest that similar ﬁndings might be
found in other Western countries.
AnyCOS should be feasible to collectwithin the context of a trial. Our
results suggest that at least 8 domains should be included. Core out-
come sets for other conditions have contained 6–11 different domains
[16,19–21]. We were not able to ask participants to identify their “top
outcome domains” for inclusion. This could be done by future studies
to potentially reduce the number of domains that should be included.
Indeed, while they are presented as independent, distinct outcome
domains to participants, in reality there is likely to be overlap. Some of
themore global outcomes could be seen to subsume other, more specif-
ic ones. Quality of life is one of these, with epilepsy quality-of-life mea-
sures often comprising a number of subscales, including emotional
well-being and physical independence [51]. Some reduction might
therefore be possible by including only global measures and excluding
some of the more speciﬁc ones.
Likemany COS studies [15,19,21], recruitment of patients was limit-
ed to those afﬁliated with a patient organization — in this case, the
British Epilepsy Association. Since people with uncontrolled epilepsy
are overrepresentedwithin such groups [43,52], this permitted efﬁcient
targeting of those who are the focus of many trials. Nevertheless, it re-
mains to be determined whether the views of those afﬁliated with
such a group are comparable to those of patients who are not. Our par-
ticipants'mean age and number of years since diagnosis were compara-
ble to the wider population with epilepsy [53]. There were, however,
more females than would be expected (~15%). Also, when compared
to the UK population [54], there was an underrepresentation of people
from minority ethnic groups.
A further potential source of bias within the recruited sample is the
relatively low response rate. Our studywas nestedwithin a longitudinal
study recruiting patient–carer dyads and achieved a response rate of ap-
proximately 10%. However, this rate is not unusual for COS studies [44]
nor for epilepsy studies that use comparable recruitment approaches;
e.g., cross-sectional studies, rather than longitudinal studies, achieved
uptake rates of 17% [55,56].
Possible reasons for the low acceptance rate and high number of
nonresponses to the invitations include the following. The infor-
mation held by the British Epilepsy Association about individuals
on their database is limited. It does not identify whether the indi-
viduals have epilepsy themselves or are persons without epilepsy
who simply contacted the Association for information. Some invi-
tations may therefore have been sent to noneligible persons for
whom the study was not relevant. To comply with the terms of
use of the database, invitations were also sent out on our behalf,
and it was not possible to send reminders to individuals who did
not respond. Finally, the contact details of people on the database
can be outdated.4.3. Conclusions
This work has for the ﬁrst time, to our knowledge, elicited the views
of PWE and their informal carers about their outcome priorities and
generated a provisional list of outcomes for inclusion in a COS for epilep-
sy. As well as conﬁrming the importance of domains previously sug-
gested as being important by health professionals, our study has
identiﬁed additional domains of importance. As a COS is not itself amea-
surement instrument, a next step will be to determine how and when
these key outcomes should be measured.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yebeh.2016.01.036.
Conﬂict of interest
The authors state that they have no conﬂicts of interest to declare.
Acknowledgments
We thank the people with epilepsy and their family and friends who
kindly participated in this study. We also acknowledge the invaluable
help of the British Epilepsy Association (Epilepsy Action) for their
assistance with participant recruitment and Ms. Abbey Robinson for
her help with data entry.
References
[1] Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al.
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efﬁcacy
and effectiveness as initial monotherapy for epileptic seizures and syndromes.
Epilepsia 2006;47(7):1094–120.
[2] Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, et al. Clinical
effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in
adults: a systematic review and economic evaluation. Health Technol Assess Apr
2005;9(15):1–157 iii-iv.
[3] Cochrane HC, Marson AG, Baker GA, Chadwick DW. Neuropsychological outcomes in
randomized controlled trials of antiepileptic drugs: a systematic reviewofmethodology
and reporting standards. Epilepsia 1998;10:1088–97.
[4] McHugh JC, Singh HW, Phillips J, Murphy K, Doherty CP, Delanty N. Outcomemeasure-
ment after vagal nerve stimulation therapy: proposal of a new classiﬁcation. Epilepsia
2007;48:375–8.
[5] Ramaratnam S, Baker GA, Goldstein LH. Psychological treatments for epilepsy.
Cochrane Database Syst Rev 2008(3) CD002029.
[6] European Medicines Agency CfMPfHU. Guideline on clinical investigations of medic-
inal products in the treatment of epileptic disorders; 2010 [Report No.].
[7] Gilliam FG. What we don't learn from clinical trials in epilepsy. Epilepsia 2003;
44(Suppl. 7):51–4.
[8] Epilepsy Action. Epilepsy Action Strategic Research Plan 2014–2018. [cited 2015
15 December]. Available from: https://www.epilepsy.org.uk/sites/epilepsy/
ﬁles/research/docs/Strategic_Research_Plan_2014-2018.pdf; 2013.
[9] Gilliam FG. Epilepsy — success in clinical practice: translating trials to practice. Eur J
Neurol 2005;12(Suppl. 4):22–9.
[10] Wieser HG, BlumeWT, Fish D, Goldensohn E, Hufnagel A, King D, et al. ILAE Commis-
sion report. Proposal for a new classiﬁcation of outcome with respect to epileptic
seizures following epilepsy surgery. Epilepsia 2001;42(2):282–6.
[11] Baker GA, Camﬁeld C, Camﬁeld P, Cramer JA, Elger CE, Johnson AL, et al. Commission
on Outcome Measurement in Epilepsy, 1994–1997: ﬁnal report. Epilepsia 1998;39:
213–31.
[12] Loring DW, Lowenstein DH, Barbaro NM, Fureman BE, Odenkirchen J, Jacobs MP, et al.
Common data elements in epilepsy research: development and implementation of
the NINDS epilepsy CDE project. Epilepsia 2011;52:1186–91.
[13] Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 2002;58(8
Suppl. 5):S9–S20.
[14] Smith D, Baker G, Davies G, DeweyM, Chadwick DW. Outcomes of add-on treatment
with lamotrigine in partial epilepsy. Epilepsia 1993;34(2):312–22.
[15] Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core
outcome domains for chronic pain clinical trials: IMMPACT recommendations.
Pain 2003;106(3):337–45.
[16] Potter S, Holcombe C, Ward JA, Blazeby JM, BS Group. Development of a core
outcome set for research and audit studies in reconstructive breast surgery. Br J
Surg 2015;102(11):1360–71.
[17] Harman NL, Bruce IA, Callery P, Tierney S, Sharif MO, O'Brien K, et al. MOMENT —
management of otitis media with effusion in cleft palate: protocol for a systematic
review of the literature and identiﬁcation of a core outcome set using a Delphi
survey. Trials 2013;14:70.
[18] Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an interna-
tional initiative to improve outcome measurement in rheumatology. Trials 2007;8:
38.
110 A.J. Noble, A.G. Marson / Epilepsy & Behavior 59 (2016) 105–110[19] Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, Ravenscroft JC. Which out-
comes should we measure in vitiligo? Results of a systematic review and a survey
among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol 2012;
167(4):804–14.
[20] Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. Patient perspective of
measuring treatment efﬁcacy: the rheumatoid arthritis patient priorities for
pharmacologic interventions outcomes. Arthritis Care Res 2010;62(5):647–56.
[21] Efﬁcace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, et al. Which
health-related quality of life aspects are important to patients with chronic myeloid
leukemia receiving targeted therapies and to health care professionals? GIMEMA
and EORTC Quality of Life Group. Ann Hematol 2012;91(9):1371–81.
[22] Williamson P, Altman D, Blazeby J, Clarke M, Gargon E. Driving up the quality and
relevance of research through the use of agreed core outcomes. J Health Serv Res
Policy 2012;17(1):1–2.
[23] Clarke M. Standardising outcomes for clinical trials and systematic reviews. Trials
2007;8:39.
[24] COMET. Core outcome measures in effectiveness trials. [cited 2015 15 December].
Available from: http://www.comet-initiative.org/studies/search.
[25] Kirkham JJ, Gargon E, Clarke M, Williamson PR. Can a core outcome set improve the
quality of systematic reviews? — a survey of the co-ordinating editors of Cochrane
review groups. Trials 2013;14:21.
[26] Kirkham JJ, Boers M, Tugwell P, Clarke M, Williamson PR. Outcome measures in
rheumatoid arthritis randomised trials over the last 50 years. Trials 2013;14:324.
[27] Bautista-Molano W, Navarro-Compán V, Landewé RB, Boers M, Kirkham JJ, van der
Heijde D. How well are the ASAS/OMERACT core outcome sets for ankylosing
spondylitis implemented in randomized clinical trials? A systematic literature re-
view. Clin Rheumatol 2014;33(9):1313–22.
[28] Appleton R, Macleod S, Martland T. Drug management for acute tonic–clonic
convulsions including convulsive status epilepticus in children. Cochrane Database
Syst Rev 2008;3(CD001905).
[29] Brigo F, Del Felice A. Melatonin as add-on treatment for epilepsy. Cochrane Database
Syst Rev 2012;6(CD006967).
[30] Hancock E, Cross H. Treatment of Lennox–Gastaut syndrome. Cochrane Database
Syst Rev 2003;3(CD003277).
[31] Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Da-
tabase Syst Rev 2008;4(CD001770).
[32] Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments for epilepsy.
Cochrane Database Syst Rev 2012;3(CD001903).
[33] Martlew J, Pulman J, Marson AG. Psychological and behavioural treatments for
adults with non-epileptic attack disorder. Cochrane Database Syst Rev 2014;
2(CD006370).
[34] Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant
focal epilepsy: an updated Cochrane review. Cochrane Database Syst Rev 2012;
9(CD001901).
[35] Offringa M, Newton R. Prophylactic drug management for febrile seizures in
children. Cochrane Database Syst Rev 2012;4(CD003031).
[36] Prasad K, Al-Roomi K, Krishnan PR, Sequeira R. Anticonvulsant therapy for status
epilepticus. Cochrane Database Syst Rev 2005;4(CD003723).
[37] Pulman J, Greenhalgh J, Marson AG. Antiepileptic drugs as prophylaxis for
post-craniotomy seizures. Cochrane Database Syst Rev 2013;2(CD007286).
[38] Schierhout G, Roberts I. Anti-epileptic drugs for preventing seizures following acute
traumatic brain injury. Cochrane Database Syst Rev 2001;4(CD000173).
[39] Khan K, Belizán JM, CROWN Initiative. The CROWN Initiative: journal editors invite
researchers to develop core outcomes in women's health. J Ovarian Res 2015;8.[40] National Institute for Health ResearchHealth Technology Assessment Programme. Guid-
ance notes for completing full proposals. [cited 2015 15 December]. Available from:
http://www.nets.nihr.ac.uk/__data/assets/pdf_ﬁle/0005/79664/FullGuidanceNotesSAF-
V1_21.pdf; 2015.
[41] Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Devel-
oping core outcome sets for clinical trials: issues to consider. Trials 2012;13:132.
[42] Kerr C, Nixon A, Angalakuditi M. The impact of epilepsy on children and adult pa-
tients' lives: development of a conceptual model from qualitative literature. Seizure
2011;20(10):764–74.
[43] Thapar A, Kerr M, Harold G. Stress, anxiety, depression, and epilepsy: investigating
the relationship between psychological factors and seizures. Epilepsy Behav 2009;
14(1):134–40.
[44] Sinha IP, Gallagher R, Williamson PR, Smyth RL. Development of a core outcome set
for clinical trials in childhood asthma: a survey of clinicians, parents, and young
people. Trials 2012;13:103.
[45] Keeley T, Khan H, Pinfold V, Williamson P, Mathers J, Davies L, et al. Core outcome
sets for use in effectiveness trials involving people with bipolar and schizophrenia
in a community-based setting (PARTNERS2): study protocol for the development
of two core outcome sets. Trials 2015;16:47.
[46] van't Hooft J, Duffy JM, Daly M, Williamson PR, Meher S, Thom E, et al. A core
outcome set for evaluation of interventions to prevent preterm birth. Obstet
Gynecol 2016;127:49–58.
[47] Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which
outcomes to measure in clinical trials: recommendations for the future based on a
systematic review of existing studies. PLoS Med 2011;8(1).
[48] Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy.
Neuropsychiatr Dis Treat 2007;3(1):117–31.
[49] Yerby MS. Pregnancy, teratogenesis and epilepsy. Neurol Clin 1994;12:749–71.
[50] Colombo F, Tapay N. Private health insurance in OECD countries. The beneﬁts and
costs for individuals and health systems. Paris: OECD; 2004.
[51] Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B.
Development and cross-cultural translations of a 31-item quality of life in epilepsy
inventory. Epilepsia 1998;39(1):81–8.
[52] Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with
epilepsy: a European study. Epilepsia 1997;38(3):353–62.
[53] Moran NF, Poole K, Bell G, Solomon J, Kendall S, McCarthy M, et al. Epilepsy in the
United Kingdom: seizure frequency and severity, anti-epileptic drug utilization
and impact on life in 1652 people with epilepsy. Seizure 2004;13(6):425–33.
[54] Ofﬁce for National Statistics. Ethnicity and national identity in England and Wales;
2011Available from: http://www.ons.gov.uk/ons/dcp171776_290558.pdfhttps://
urldefense.proofpoint.com/v2/url?u=http-3A__www.ons.gov.uk_ons_dcp171776-
5F290558.pdf&d=AwMGaQ&c=
WknmpdNpvrlj2B5K1aWVqL1SOiF30547pqSuOmtwXTQ&r=
Ke2Ou4y6xYFa6e5FXO0Gpxk9gZqLbQACUg3BDgQOe7E&m=nR0-w_
lDhKqzIhm7LXsdOSIYFHSFmDUywmB1Wqxp4n4&s=
CeeMcc7heX8bN5zlmfeUbfMmT9sM2kamctfKovWwzf0&e=.
[55] Crawford P, Hudson S. Understanding the information needs of women with
epilepsy at different life stages: results of the ‘Ideal World’ survey. Seizure 2003;
12(7):502–7.
[56] Jacoby K, Jacoby A. Epilepsy and insurance in the UK: an exploratory survey of the
experiences of people with epilepsy; 2004 884–93.
